PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Phase 2

Completed

Conditions: Ocular Hypertension
Primary Open-Angle Glaucoma

Interventions: Drug: Latanoprost Vehicle
Drug: PF-04217329 - Middle Dose
Drug: PF-4217329 - Highest Dose
Drug: PF-04217329 - Lowest Dose
Drug: PF-04217329 - Low Dose
Drug: Latanoprost 0.005%
Drug: PF-04217329 - High Middle Dose
Drug: PF-04217329 - High Dose
Drug: PF-04217329 - Vehicle

First Posted Date: 2007-12-13

Last Posted Date: 2021-04-30

Lead Sponsor: Pfizer

Target Recruit Count: 318

Registration Number: NCT00572455

Locations: 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸
Sall Research Medical Center, Artesia, California, United States
🇺🇸
North Bay Eye Associates, Inc., Petaluma, California, United States

and more 20 locations

Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus

Phase 4

Completed

Conditions: Pneumonia, Ventilator-Associated

Interventions: Drug: Linezolid
Drug: Vancomycin

First Posted Date: 2007-12-13

Last Posted Date: 2010-06-09

Lead Sponsor: Pfizer

Target Recruit Count: 149

Registration Number: NCT00572559

Locations: 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico

Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

Phase 2

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: AG-013736

First Posted Date: 2007-12-10

Last Posted Date: 2019-06-05

Lead Sponsor: Pfizer

Target Recruit Count: 64

Registration Number: NCT00569946

Locations: 🇯🇵
Tokyo Women's Medical University Medical Center East, Arakawa-ku, Tokyo, Japan
🇯🇵
Osaka University Hospital, Osaka, Japan
🇯🇵
Akita University Hospital, Akita, Japan

and more 15 locations

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

Phase 2

Completed

Conditions: Insomnia

Interventions: Drug: PD 0200390
Drug: Placebo

First Posted Date: 2007-12-10

Last Posted Date: 2012-07-25

Lead Sponsor: Pfizer

Target Recruit Count: 682

Registration Number: NCT00569972

Locations: 🇨🇦
Pfizer Investigational Site, Toronto, Ontario, Canada

Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo

Phase 2

Terminated

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: PF-02545920

First Posted Date: 2007-12-10

Last Posted Date: 2017-12-20

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT00570063

Locations: 🇺🇸
Glendale Adventist Medical Center, Glendale, California, United States
🇺🇸
California Clinical Trials Medical Group, Inc., Glendale, California, United States
🇺🇸
Telecare-Cresta Loma, Lemon Grove, California, United States

and more 6 locations

RN624 For Pain Of Post-Herpetic Neuralgia

Phase 2

Completed

Conditions: Neuralgia, Postherpetic

Interventions: Drug: RN624
Drug: Placebo

First Posted Date: 2007-12-06

Last Posted Date: 2021-05-28

Lead Sponsor: Pfizer

Target Recruit Count: 99

Registration Number: NCT00568321

Locations: 🇺🇸
Innovative Research of West Florida, Inc., Largo, Florida, United States
🇺🇸
International Research Center, Towson, Maryland, United States
🇺🇸
Neurology Clinical Research, Inc., Sunrise, Florida, United States

and more 28 locations

A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: PF-3463275

First Posted Date: 2007-12-04

Last Posted Date: 2008-10-02

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT00567203

Locations: 🇺🇸
Pfizer Investigational Site, Willingboro, New Jersey, United States

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: PF-04494700

First Posted Date: 2007-12-03

Last Posted Date: 2018-11-30

Lead Sponsor: Pfizer

Target Recruit Count: 402

Registration Number: NCT00566397

Locations: 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States

A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Drug: SD-6010
Drug: Placebo

First Posted Date: 2007-11-30

Last Posted Date: 2016-12-30

Lead Sponsor: Pfizer

Target Recruit Count: 1457

Registration Number: NCT00565812

Locations: 🇺🇸
Plaza Medical Imaging, Santa Ana, California, United States
🇺🇸
Rapid Medical Research, Inc., Cleveland, Ohio, United States
🇺🇸
The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States

and more 169 locations

Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

Phase 4

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Placebo
Drug: Etanercept
Drug: Methotrexate

First Posted Date: 2007-11-30

Last Posted Date: 2015-08-10

Lead Sponsor: Pfizer

Target Recruit Count: 834

Registration Number: NCT00565409

Locations: 🇬🇧
Pfizer Investigational Site, Dudley, West Midlands, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy